Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape

Understanding the research and development (R&D) pipeline for neglected diseases as well as the spectrum of organizations participating in developing these new drugs and vaccines is essential to evaluate the eciency and eectiveness of current R&D models and to inform the design of new programs and initiatives to ll gaps in the neglected disease R&D pipeline. However, this type of analysis has been hindered in part because neglected disease pipelines have not been systematically tracked. Millions of lives could be saved through faster and more effi-cient R&D. It is critical to target our resources and R&D efforts to provide the greatest benet to the world’s poor.

In 2011, BIO Ventures for Global Health (BVGH) released the new and expanded Global Health Primer, a report and online database of compiled drug and vaccine development pipelines for neglected diseases. Using this unique dataset, we explored for the rst time the extent to which dierent types of organizations are participating in drug and vaccine development for a broad range of neglected diseases. BVGH’s new analysis of product developers participating in drug and vaccine development revealed:

........(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다